Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
Agios Pharmaceuticals (NASDAQ: AGIO), a biotechnology company focused on cellular metabolism and PK activation therapies for rare diseases, has announced its upcoming participation in the 2025 RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for May 21, 2025, at 8:00 AM ET. Investors and interested parties can access the live webcast through the Investors section of Agios' website under "Events & Presentations." A replay will remain available on the company's website for a minimum of two weeks after the presentation.
Agios Pharmaceuticals (NASDAQ: AGIO), un'azienda biotecnologica specializzata in terapie per il metabolismo cellulare e l'attivazione di PK per malattie rare, ha annunciato la sua partecipazione alla 2025 RBC Capital Markets Global Healthcare Conference. La presentazione è prevista per il 21 maggio 2025 alle 8:00 ET. Investitori e interessati potranno seguire la diretta streaming nella sezione Investitori del sito web di Agios, sotto "Eventi e Presentazioni". La registrazione rimarrà disponibile sul sito per almeno due settimane dopo l'evento.
Agios Pharmaceuticals (NASDAQ: AGIO), una compañía biotecnológica enfocada en terapias de metabolismo celular y activación de PK para enfermedades raras, ha anunciado su próxima participación en la Conferencia Global de Salud 2025 de RBC Capital Markets. La presentación está programada para el 21 de mayo de 2025 a las 8:00 AM ET. Los inversores y partes interesadas podrán acceder a la transmisión en vivo a través de la sección de Inversores en el sitio web de Agios, bajo "Eventos y Presentaciones". La repetición estará disponible en el sitio web de la compañía durante al menos dos semanas después de la presentación.
Agios Pharmaceuticals (NASDAQ: AGIO)는 희귀 질환을 위한 세포 대사 및 PK 활성화 치료에 중점을 둔 생명공학 회사로, 2025 RBC Capital Markets 글로벌 헬스케어 컨퍼런스에 참여할 예정임을 발표했습니다. 발표는 2025년 5월 21일 오전 8시(동부 시간)에 진행됩니다. 투자자 및 관심 있는 분들은 Agios 웹사이트의 투자자 섹션 내 "이벤트 및 프레젠테이션"에서 라이브 웹캐스트를 시청할 수 있습니다. 발표 후 최소 2주간 웹사이트에서 다시보기 서비스를 제공합니다.
Agios Pharmaceuticals (NASDAQ : AGIO), une entreprise biotechnologique spécialisée dans les thérapies du métabolisme cellulaire et l’activation de PK pour les maladies rares, a annoncé sa participation à la conférence mondiale sur la santé RBC Capital Markets 2025. La présentation est prévue pour le 21 mai 2025 à 8h00 ET. Les investisseurs et parties intéressées pourront accéder au webcast en direct via la section Investisseurs du site web d’Agios sous « Événements et Présentations ». Une rediffusion sera disponible sur le site de la société pendant au moins deux semaines après la présentation.
Agios Pharmaceuticals (NASDAQ: AGIO), ein Biotechnologieunternehmen, das sich auf Zellstoffwechsel und PK-Aktivierungstherapien für seltene Krankheiten spezialisiert hat, hat seine Teilnahme an der 2025 RBC Capital Markets Global Healthcare Conference angekündigt. Die Präsentation ist für den 21. Mai 2025 um 8:00 Uhr ET geplant. Investoren und Interessierte können das Live-Webcast über den Bereich Investoren auf der Agios-Website unter "Veranstaltungen & Präsentationen" verfolgen. Eine Aufzeichnung wird mindestens zwei Wochen nach der Präsentation auf der Website verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET.
The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
FAQ
When is Agios Pharmaceuticals (AGIO) presenting at the RBC Capital Markets Healthcare Conference 2025?
How can investors access Agios Pharmaceuticals' (AGIO) presentation at the RBC Healthcare Conference?
How long will the replay of Agios Pharmaceuticals' (AGIO) RBC conference presentation be available?
What is Agios Pharmaceuticals' (AGIO) main business focus?
